Lupin Q1 FY24 Growth Metrics and ESG Goals
Other Markets: Key Highlights
Other Key Markets driving growth
Emerging Markets: Steady growth
EU
EU
•
Luforbec, Namuscla and
levetiracetam growing
Brazil
Completed Medisol acquisition
in France
8th largest generics player¹
South Africa
5% YoY growth to reach ZAR 295
mn sales in Q1 FY24
Mexico
4th largest generics player²
Australia
SCP acquisition performing well
API + Global
Institutional
·
•
Note:
1. IQVIA May 23 by sales
2. IQVIA Midas Sales Audit Mar-23
BRL 75 mn sales in Q1 FY24
(growth of 30% YoY) driven by
ibuprofen & acquired portfolio
In reference market, ranks 2nd3
Recorded 59% YoY decline with
MXN 86.2 Mn, due to impact of
stock-outs
Philippines
YoY growth in 7% driven by renal,
women's health
API revenues grew 32% YoY in Q1 FY24 due to core API business growth
Continued leadership in anti-TB Institutional business and increasing ARV registrations
3. IQVIA MAT May-23
LUPIN
8View entire presentation